Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-β signaling pathway

Biochemical and Biophysical Research Communications

Volumn 393, Issue 3, 2010, Pages 536-541

  Min, Ae Kyung ^a   Kim, Mi Kyung ^a   Seo, Hye Young ^b   Kim, Hye Soon ^a   Jang, Byoung Kuk ^a   Hwang, Jae Seok ^a   Choi, Hueng Sik ^c   Lee, Ki Up ^d   Park, Keun Gyu ^a   Lee, In Kyu ^b  

^a Keimyung University School of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Chonnam National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Alpha lipoic acid; Hepatic fibrosis; Plasminogen activator inhibitor 1; Transforming growth factor

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIOCTIC ACID; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; LIVER CELL; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LIVER CIRRHOSIS; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SP1 TRANSCRIPTION FACTOR; THIOCTIC ACID; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 77949261524     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.050     Document Type: Article

References (34)

1. Friedman S.L. Molecular mechanisms of hepatic fibrosis and principles of therapy. J. Gastroenterol. 32 (1997) 424-430
2. Albanis E., and Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis. 5 (2001) 315-334
3. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) 99-112
4. del Pilar Alatorre-Carranza M., Miranda-Díaz A., Yañez-Sánchez I., Pizano-Martínez O., Hermosillo-Sandoval J.M., Vázquez-Del Mercado M., Hernández-Hoyos S., Martínez-Abundis R., Fafutis-Morris M., Segura-Ortega J., and Delgado-Rizo V. Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins. BMC Gastroenterol. 31 (2009) 81
5. Vaillant B., Chiaramonte M.G., Cheever A.W., Soloway P.D., and Wynn T.A. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J. Immunol. 167 (2001) 7017-7026
6. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275 (2000) 2247-2250
7. Gressner A.M., Weiskirchen R., Breitkopf K., and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 7 (2002) 793-807
8. Liu X., Hu H., and Yin J.Q. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 26 (2006) 8-22
9. Breitkopf K., Haas S., Wiercinska E., Singer M.V., and Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol. Clin. Exp. Res. 29 (2005) 121-131
10. Nakamura T., Ueno T., Sakamoto M., Sakata R., Torimura T., Hashimoto O., Ueno H., and Sata M. Suppression of transforming growth factor-beta results in upregulation of transcription of regeneration factors after chronic liver injury. J. Hepatol. 41 (2004) 974-982
11. Nakamura T., Sakata R., Ueno T., Sata M., and Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32 (2000) 247-255
12. 4 in rats: role of TGF-beta modulation and oxidative stress. Fundam. Clin. Pharmacol. 22 (2008) 417-427
13. Yang C., Zeisberg M., Mosterman B., Sudhakar A., Yerramalla U., Holthaus K., Xu L., Eng F., Afdhal N., and Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124 (2003) 147-159
14. Nagamine Y. Transcriptional regulation of the plasminogen activator inhibitor type 1-with an emphasis on negative regulation. Thromb. Haemost. 100 (2008) 1007-1013
15. Wang H., Zhang Y., and Heuckeroth R.O. Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice. Hepatology 45 (2007) 1527-1537
16. Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., and Prager G.W. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol. Sci. 17 (2002) 56-61
17. McCrudden R., and Iredale J.P. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol. Histopathol. 15 (2000) 1159-1168
18. Arthur M.J., Mann D.A., and Iredale J.P. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J. Gastroenterol. Hepatol. 13 (1998) 33-38
19. Bergheim I., Guo L., Davis M.A., Duveau I., and Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther. 316 (2006) 592-600
20. Wang H., Vohra B.P., Zhang Y., and Heuckeroth R.O. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 42 (2005) 1099-1108
21. Wang H., Zhang Y., and Heuckeroth R.O. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 581 (2007) 3098-3104
22. Hu P.F., Chen H., Zhong W., Lin Y., Zhang X., Chen Y.X., and Xie W.F. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J. Hepatol. 51 (2009) 102-113
23. Svegliati-Baroni G., Saccomanno S., van Goor H., Jansen P., Benedetti A., and Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 21 (2001) 1-12
24. Hui A.Y., and Friedman S.L. Molecular basis of hepatic fibrosis. Expert Rev. Mol. Med. 5 (2003) 1-23
25. Kretzschmar M., Doody J., Timokhina I., and Massagué J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 13 (1999) 804-816
26. Massagué J., and Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19 (2000) 1745-1754
27. Javelaud D., and Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24 (2005) 5742-5750
28. Vayalil P.K., Iles K.E., Choi J., Yi A.K., Postlethwait E.M., and Liu R.M. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am. J. Physiol. Lung Cell. Mol. Physiol. 293 (2007) 1281-1292
29. Lee W.J., Lee I.K., Kim H.S., Kim Y.M., Koh E.H., Won J.C., Han S.M., Kim M.S., Jo I., Oh G.T., Park I.S., Youn J.H., Park S.W., Lee K.U., and Park J.Y. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2488-2494
30. Park K.G., Min A.K., Koh E.H., Kim H.S., Kim M.O., Park H.S., Kim Y.D., Yoon T.S., Jang B.K., Hwang J.S., Kim J.B., Choi H.S., Park J.Y., Lee I.K., and Lee K.U. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 48 (2008) 1477-1486
31. Guo B., Inoki K., Isono M., Mori H., Kanasaki K., Sugimoto T., Akiba S., Sato T., Yang B., Kikkawa R., Kashiwagi A., Haneda M., and Koya D. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int. 68 (2005) 972-984
32. Schuppan D., and Afdhal N.H. Liver cirrhosis. Lancet 371 (2008) 838-851
33. Eddy A.A. Plasminogen activator inhibitor-1 and kidney. Am. J. Physiol. Renal Physiol. 283 (2002) 209-220
34. Wang H., Vohra B.P., Zhang Y., and Heuckeroth R.O. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 42 (2005) 1099-1108